Doctors Urge the Public to Seek Help for Cancer Screenings as Sharp Decline in Care Means Thousands of Untreated Cases
In March and April just 97 cases of prostate cancer were diagnosed throughout Hartford Healthcare compared with 233 cases in 2019. The stark decline holds true for digestive cancers with a 42 percent decline in diagnoses and breast cancer with a 30 percent decline in diagnoses compared to the same period in 2019.
Smilow Torrington supports fellow healthcare workers and community
Smilow Cancer Hospital Care Center at Torrington, in collaboration with Agriventures Agway of Litchfield, provided a donation of flower and vegetable seed packets to the physicians, nurses, and staff at Charlotte Hungerford Hospital in Torrington.
Study Conducted at Yale Cancer Center Shows Clinical Evidence of Anti-Tumor Activity in Patients with Metastatic Castration-Resistant Prostate Cancer
Results of a clinical trial conducted by researchers at the Yale Cancer Center have shown that ARV-110, an androgen receptor PROTAC® protein degrader, demonstrates anti-tumor responses in patients with metastatic castration-resistant prostate cancer.
Yale Cancer Center Investigator Shows Chemotherapy Combined with Low Doses of Radiotherapy Improves Survival for Patients with Rare Lymphoma
According to findings of a national study, the addition of low-dose, whole-brain radiotherapy (LD-WBRT) combined with chemotherapy improved progression-free survival (PFS) in patients with primary central nervous system lymphoma (PCNSL). These results are to be presented May 30 at 11:00 a.m., during the virtual Scientific Program at the annual meeting of the American Society of Clinical Oncology (ASCO).
Encouraging New Data from Yale Cancer Center Shows Correlation to PD-L1 Expression from KEYNOTE-061
New findings led by Yale Cancer Center researchers show data sharing improved survival for patients with advanced gastric cancers. The data will be presented on May 30 at 11:00 a.m., during the virtual Scientific Program at the annual meeting of the American Society of Clinical Oncology (ASCO).
Yale Cancer Center Study Shows Profound Benefit with Targeted Therapy for Patients with Early Stage NSCLC
According to findings led by researchers at Yale Cancer Center, treatment with the targeted therapy osimertinib following surgery significantly improves disease-free survival (DFS) in patients with early-stage, non-small cell lung cancer (NSCLC) with EGFR gene mutations.
Video: PARP Inhibition in Castration-resistant Prostate Cancer - Daniel Petrylak
Dr. Dan Petrylak joins Tom Keane to discuss PARP inhibition in castration-resistant prostate cancer. In this lecture, Dr. Petrylak discusses the germline DNA repair mutations involved in prostate cancer. This is a state of the art lecture establishing the rationale for the clinical trials evaluating PARP inhibitors in metastatic castration-resistant prostate cancer.
Exploring the frontiers of immunity and healing
During a 1989 lecture at the Cold Spring Harbor Symposium on Quantitative Biology, Yale School of Medicine professor Charles Janeway, MD, hypothesized the existence of an innate immune system and special receptors on immune cells (currently known as toll-like receptors) that trigger the body's response to infection. Janeway's research later confirmed his insights, providing the foundation of future endeavors exploring the intricacies of the human immune response. New discoveries continue to reveal an exquisitely tuned immune system in which inflammatory responses and healing are initiated and regulated by known and unknown mechanisms.
Yale Cancer Center Study Demonstrates Impact of Both Inherited and Acquired Mutations on Cancer
The common belief that tumors arise via activation of a few genes that “drive” cancer development is unsupported by a widespread investigation into those genes and others in three large patient genetic databases, according to a study led by Yale Cancer Center researchers.